IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Abstract

IDEC-C2B8 chimeric anti-CD20 mAb therapy is well tolerated and has clinical activity in patients with relapsed B-cell lymphoma. The 375-mg/m2 dose has been selected for a phase II trial in patients with relapsed low-grade or follicular B-cell lymphoma.

References

Page 1

	Year	Citations
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 ME Reff, K Carner, KS Chambers, Blood	1994	1.9K
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma DG Maloney, TM Liles, DK Czerwinski, Blood	1994	747
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation KC Anderson, MP Bates, BL Slaughenhoupt, Blood	1984	691
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support Oliver W. Press, Janet F. Eary, Frederick R. Appelbaum, New England Journal of Medicine	1993	650
Radioimmunotherapy of B-Cell Lymphoma with [<sup>131</sup>I]Anti-B1 (Anti-CD20) Antibody Mark Kaminski, Kenneth Zasadny, Isaac R. Francis, New England Journal of Medicine	1993	548
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Oliver W. Press, F. R. Appelbaum, Paul J. Martin, The Lancet Lymphoid NeoplasiaCell TherapyTransplantationPhase Ii TrialMedicine	1995	432
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Mark Kaminski, Kenneth Zasadny, Isaac R. Francis, Journal of Clinical Oncology	1996	401
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. James K. Bubien, Li-Na Zhou, P. Darwin Bell, The Journal of Cell Biology ImmunologyBlood CellImmunologic MechanismB LymphocytesEctopic Cell Types	1993	351
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. David A. Einfeld, Joseph P. Brown, Mary A. Valentine, The EMBO Journal Molecular ImmunologySignal TransductionImmunologyReceptor (Biochemistry)Multiple Transmembrane Domains	1988	277
The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. Thomas F. Tedder, A W Boyd, AS Freedman, The Journal of Immunology	1985	230

Page 1